SCHEMBL7202711

SCHEMBL7202711

CCN(CCCNCc1ccccc1)Cc1ccccc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 2/20 0.57
TMEM97 Q5BJF2 1/20 0.57
MAOA P21397 1/20 0.55
APP P05067 3/20 0.54
CHRM2 P08172 2/20 0.53
MAOB P27338 2/20 0.50
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
TDP1 Q9NUW8 1/20 0.50
HTR1A P08908 1/20 0.50
ADRA2A P08913 1/20 0.50
CHRM1 P11229 1/20 0.50
DRD1 P21728 1/20 0.50
SLC6A2 P23975 1/20 0.50
SLC6A4 P31645 1/20 0.50
ADRA1A P35348 1/20 0.50
OPRM1 P35372 1/20 0.50
DRD3 P35462 1/20 0.50
SLC6A3 Q01959 1/20 0.50
KCNH2 Q12809 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7207674 0.95 MAOA (0.58) SIGMAR1TMEM97MAOAAPPCHRM2
SCHEMBL7206731 0.94 MAOA (0.61) SIGMAR1TMEM97MAOAAPPCHRM2
SCHEMBL7202285 0.94 MAOA (0.61) SIGMAR1TMEM97MAOAAPPCHRM2
SCHEMBL6164283 0.92 MAOA (0.60) SIGMAR1TMEM97MAOACHRM2MEN1
SCHEMBL2538898 0.90 MEN1 (0.53) SIGMAR1TMEM97MAOAAPPCHRM2
SCHEMBL9326853 0.89 APP (0.56) APPCHRM2MAOBHTR1AADRA2A
SCHEMBL9185975 0.85 SIGMAR1 (0.44) SIGMAR1TMEM97MAOAAPPCHRM2
SCHEMBL10941196 0.84 SIGMAR1 (0.66) SIGMAR1TMEM97MAOACHRM2MEN1
SCHEMBL5985351 0.83 MAOA (0.58) SIGMAR1TMEM97MAOACHRM2MEN1
SCHEMBL17346065 0.83 APP (0.48) APPCHRM2MAOBHTR1AADRA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030229037-A1 Novel cationic amphiphiles MASSING ULRICH (DE) 2003-12-11 US disclosed
EP-1261620-A2 CATIONIC AMPHIPHILES FOR USE IN NUCLEIC ACID TRANSFECTION Roche Diagnostics Corporation (US) 2002-12-04 EP disclosed
WO-2001057064-A2 CATIONIC AMPHIPHILES FOR USE IN NUCLEIC ACID TRANSFECTION ROCHE DIAGNOSTICS CORPORATION (US) 2001-08-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030229037-A1 Novel cationic amphiphiles ABHD16A, APMAP, ABCB4 SIGMAR1 2152/4885TMEM97 384/4885MAOA 3723/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.